TransMedics Group/$TMDX
1D1W1MYTD1Y5YMAX
Capital at risk
About TransMedics Group
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
- Ticker
- $TMDX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 898
- Headquarters
- Andover, United States
- Website
- www.transmedics.com
TMDX Metrics
BasicAdvanced
$3B
21.81
$4.01
1.88
-
Price and volume
Market cap
$3B
Beta
1.88
52-week high
$156.00
52-week low
$60.11
Average daily volume
800K
Financial strength
Current ratio
6.625
Quick ratio
5.869
Long term debt to equity
1.629
Total debt to equity
1.675
Interest coverage (TTM)
3.84%
Profitability
EBITDA (TTM)
115.629
Gross margin (TTM)
58.69%
Net profit margin (TTM)
22.69%
Operating margin (TTM)
12.21%
Effective tax rate (TTM)
-109.08%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
4.33%
Return on equity (TTM)
36.28%
Valuation
Price to earnings (TTM)
21.811
Price to revenue (TTM)
4.496
Price to book
5.85
Price to tangible book (TTM)
5.99
Price to free cash flow (TTM)
38.026
Free cash flow yield (TTM)
2.63%
Free cash flow per share (TTM)
2.303
Growth
Revenue change (TTM)
25.82%
Earnings per share change (TTM)
98.94%
3-year revenue growth (CAGR)
64.17%
3-year earnings per share growth (CAGR)
92.86%
What the Analysts think about TMDX
Analyst ratings (Buy, Hold, Sell) for TransMedics Group stock.
Analyst projections of the future price of TransMedics Group stock.
Bulls say / Bears say
TransMedics delivered Q2 2026 revenue of $189.9 million, up 21% year over year, and raised the low end of its full-year revenue outlook to $737 million while retaining a $757 million upper bound. The outlook implies approximately 22% to 25% growth for 2026. (TransMedics)
The higher-margin, recurring service ecosystem is scaling: Q2 service revenue increased 29% to $78.8 million, faster than product revenue growth, while TransMedics owned 22 aircraft and completed its PAD Aviation investment to build a broader organ-transplant logistics network. (SEC)
There are potential clinical and market-expansion catalysts beyond current guidance. In May, TransMedics unveiled CHOPS to support enrollment in the OCS ENHANCE Heart Part B and OCS DENOVO Lung trials, while management’s 2026 outlook assumes no incremental revenue from those trials, leaving room for upside if development progresses favorably. (TransMedics)
Profitability is under pressure despite continued growth: Q2 2026 operating margin fell to 12.5% from 23.2% a year earlier, while first-half operating margin declined to 10.2% from 21.3% as TransMedics increased operating and growth investments. (SEC)
The aviation-led logistics strategy adds execution and regulatory risk. TransMedics specifically cites FAA compliance, pilot availability and operational disruptions as risks, while its PAD Aviation investment is excluded from 2026 revenue guidance and has yet to contribute to the outlook. (SEC; TransMedics)
Financial-governance execution remains a watchpoint: the June 2026 filing said a previously identified material weakness in inventory controls had not yet been remediated, and the company is also transitioning to a new CFO effective September 21, 2026. (SEC; TransMedics)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
TMDX Financial Performance
Revenues and expenses
TMDX Earnings Performance
Company profitability
Upcoming events
No upcoming events
TMDX News
AllArticlesVideos
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
Business Wire3 days ago
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Newsfile Corp4 weeks ago
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
MarketBeat1 month ago
Funds containing TMDX
AllUSDGBPEUR
Fund name | Fund size | $TMDX weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.18% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.18% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.